DELX stock sentiment todayDelex Healthcare Group Inc
Sentiment verdict
Gossip first, financials second — COLD at 95% confidence.
Last updated · cached analysis, refreshes periodically
DELX
Delex Healthcare Group IncA highly speculative 'Expert Market' penny stock with zero liquidity, no recent disclosures, and significant delisting risks.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for DELX. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by silence and 'caveat emptor' warnings. As an OTCPK security priced under a penny with no recent headlines, the market view is that this is a 'zombie' ticker or a defunct shell with no active retail or institutional interest.
- ·Lack of public financial reporting
- ·Expert Market designation restricting most retail buying
- ·Total absence of news or corporate catalysts since 2022-2023
- ·Extreme illiquidity leading to flat price action
Financial
The company suffers from a lack of transparency; it is currently 'Dark and Defunct' in terms of SEC reporting. Historical data suggested a focus on pharmaceutical distribution in Southeast Asia, but without current audited statements, the balance sheet must be assumed compromised.
- ·Market Cap: N/A (Undetermined due to share count uncertainty)
- ·Price: $0.0073 (Deep sub-penny territory)
- ·Reporting Status: Non-compliant / Pink No Information
- ·Liquidity: Near-zero average daily volume
Risks
- ·Permanent loss of capital due to lack of exit liquidity
- ·Regulatory revocation of registration (SEC Rule 15c2-11)
- ·Complete absence of fundamental oversight or audited financials
- ·Potential for massive dilution if convertible debt holders are active
Peer temperature
How direct competitors stack up against DELX right now.
- NEUTRALZENEZeneus Limited
COLDER — Similar OTC pharmaceutical profile but even lower volume and higher insolvency risk.
See full analysis → - HOTEUROEuroseas Ltd
HOTTER — Though a different sector, as a micro-cap it offers actual audited earnings and a 5%+ dividend yield compared to DELX's zero transparency.
See full analysis → - HOTPLXProtallix BioTherapeutics
HOTTER — A legitimate biotech peer with FDA-approved products and institutional backing that makes DELX look like a ghost entity.
See full analysis →
- DELX-2.7%
- ZENE—
- EURO—
- PLX+9.4%
AI-generated analysis for informational purposes only. Not financial advice.